The c-kit tyrosine kinase receptor can be activated by mutations in several different regions of the gene. In adult AML, mutations have been described especially in cases with good risk cytogenetic abnormalities. The detection of such mutations is clinically relevant, given the availability of kit tyrosine kinase inhibitors, such as imatinab mesylate (STI571). We retrospectively studied 165 de novo pediatric AML samples, included in the AML-BFM studies 87/93 and Dutch BFM-based ANLL 87/94 protocols, for c-kit exon 8 and 17 mutations by PCR amplification of genomic DNA. Mutations were characterized by denaturing HPLC and direct DNA sequencing. Mutations of c-kit exon 8 were found in 7/165 (4,2%) de novo AML patients. Mutations of exon 17 were found in 11/165 (6.7%) de novo AML cases. Thus, 10.9% (18/165) of de novo pediatric AML cases had mutations in c-kit exons 8 or 17. Mutations in exon 8 included different deletions of codons 417-419, with and without gcc insertions. The exon 17 mutations included: N822K, n=2; Y823D, n=1; D816Y, n=2; D816V, n=6. Patient characteristics: median age 7.8 years, WBC 21.2x109/l, sex: 11 male, 7 female, FABclassification: 1xM2, 5xM2au, 3xM4, 5xM4eo, 2xM5, 1xM6. Cytogenetics: t(9;11), n=2; t(10;11)(q11;p11), n=1; t(8;21), n=6; inv(16), n=5; normal, n=2; unknown n=2. There was no difference in age (p=0.3) or WBC (p=0.4) between kit mutated and non-mutated patients. FAB M2/M4 (including M2au and M4eo) was found in 82% of c-kit mutated cases vs. 49% in non-mutated cases (p<0,01). Good risk cytogenetics (inv(16), t(8;21), t(9;11)) were found in 75% of c-kit mutated vs. 20% in non-mutated cases (p<0.001). Of 158/165 AML cases also the flt3 internal tandem duplication status was known. None occured in the c-kit mutated group (n=17) vs. 16 flt3/ITD's in the 147 non-mutated samples. In conclusion: 1) c-kit exon 8 and 17 mutations occur in 10.4% of pediatric AML cases, especially in the good risk cytogenetic subgroups: t(8;21), inv(16) and t(9;11) 2) mutations in c-kit are as common as flt3/ITD mutations in pediatric AML 3) activated c-kit may be a rational target for c-kit inhibitors in a subset of patients with pediatric AML. Relapsed childhood acute myeloid leukemia (cAML) patients have poor clinical prognosis. The aim of the study was the analysis of the in vitro drug resistance profile on relapse in cAML in comparison to newly diagnosed cAML. The results of 98 cAML samples tested by the MTT assay were analyzed. Age of patients: 1 month -18 years. Eighteen samples (18%) were excluded from the further analysis due to spontaneous apoptosis of blasts in 4-days culture, small percentage of myeloblasts in the sample either in the beginning or at the end of the assay, infection, and formation of clots in the sample. Finally, 20 relapsed samples were compared with the results of 60 de novo cAML. Up to 29 drugs were tested for each patient. Apart from agents which are in routine use for childhood acute leukemias study, we have also tested a number of drugs, which are not used in the therapy of leukemias such as epirubicin, actinomycin D, mitomycin C, dacarbazine, cisplatine, carboplatine, paclitaxel and docetaxel, but really none of these drugs showed ability to circumvent resistance of myeloblasts. No significant differences between drug resistance on diagnosis and at relapse in cAML was found. We did not find any higher resistance of myeloblasts on relapse, when compared to de novo cAML. On the contrary, better sensitivity on relapse was found against melphalan (3-fold, p=0.047), and possibly against thiotepa (4-fold, p=0.060), 4-HOO-ifosfamide (3-fold, 0.086), and cladribine (3-fold, p=0.672). The in vitro drug resistance profile in de novo cAML was compared between the group of 13 patients who have died due to refractory or relapsing disease with the group of patients who stayed in remission. The myeloblasts of poor-prognosis patients already on diagnosis showed higher resistance to cisplatine (6-fold, p=0.014), carboplatin (3-fold, p=0.014), and cytarabine (2-fold, p=0.037), when compared to the cells of other patients. In summary, cellular drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis. Possibly, in vitro resistance to platinum derivatives might be of prognostic relevance in cAML. The study was supported by grant KBN 6PO5E08221. The estimated 20-years incidence of second malignancies is 8%, including leukemias in 8% (AML in 90%). About 5% of all AML cases are secondary malignancies. The prognosis in childhood AML is related to resistance to a large number of drugs (Zwaan et al, Blood 2000; 96:2879) . sAML is reported to have poor outcome, however no data were reported so far about drug resistance in children with sAML. We described three cases of sAML patients, aged 2-10 at first diagnosis of medulloblastoma (MB, therapy protocol: PNET study trial III), neuroblastoma (NBL, protocol: Tokyo) and rhabdomyosarcoma (RMS, protocol: CWS96) . No patient presented marrow involvement. sAML developed 3-28 months after therapy of first malignancy was withdrawn. FAB subtype: M1 (after MDS with monosomy of chromosome 7), M2 and M5 (both presented with hyperleukocytosis). Myeloblasts were tested for their chemosensitivity by the MTT assay; 14-19 drugs were tested for each sample (cytarabine, fludarabine, cladribine, daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, prednisolone, vincristine, etoposide, treosulfan, melphalan, thiotepa, mafosfamide, . The LC50 results for each drug were compared with the median LC50 value of 40 children with AML de novo (Styczynski et al, Leuk Lymph 2002; 43:1843) . Results: The samples of sAML did not show any overall trend in drug resistance. Taken together, all 52 results obtained for 19 drugs, did not differ significantly from median LC50 values of de novo AML, however two patients showed relatively sensitive profile, and 1 (M2, previous NBL) relatively resistant profile to most of tested drugs. The most sensitive profile was observed in patient with M5 subtype (previous RMS). Large inter-patient variability of LC50 values for almost all drugs was observed with the exception of cladribine. All 3 samples were >5-fold more sensitive to cladribine than the median of AML de novo group. No drug was found for which the cells showed higher resistance. In vitro sensitivity to drugs used in the therapy of first malignancy was differentiated and reflected the overall resistance profile for each patient more than resistance to any specific drug.
P22 CELLULAR DRUG RESISTANCE IN CHILDHOOD AML ON RELAPSE IS NOT HIGHER THAN AT FIRST DIAGNOSIS; IN VITRO RESISTANCE TO PLATINUM COMPOUNDS MIGHT HAVE PREDICTIVE VALUE FOR NEWLY DIAGNOSED PATIENTS

P23 EX VIVO CHEMORESISTANCE IN CHILDREN WITH ACUTE MYELOID LEUKEMIA DEVELOPING AS A SECOND MALIGNANCY (sAML)
Supported by grant KBN 6PO5E08221.
P24 NITRIC OXIDE INDUCES GROWTH SUPPRESSION AND APOPTOSIS, INCREASES PREDNISOLONE SENSITIVITY, AND MODULATES CELL CYCLE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA CELLS, BUT NOT IN NORMAL MARROW CELLS J. Styczynski Medical University of Bydgoszcz, BYDGOSZCZ, Poland
Recent data suggest that sodium nitroprusside (SNP), a nitric oxide donor, might have cytotoxic effects on leukemic cells. The objective of this study was the analysis of modulatory effect of SNP on ex-vivo prednisolone (PRN) cytotoxicity in 23 childhood ALL samples, CCRF-CEM cell line, and in normal bone marrow (NMC). Methods included four-element model of modulation effect testing (tested cells ± SNP, tested cells + PRN ± SNP) by the MTT assay. The final concentration of SNP was always 30 mcM, and for PRN ranged 0.0076-250 mcg/ml. Cell cycle arrest, sub-G1-phase and induction of early apoptosis expressed by annexin-V staining were analyzed by flow cytometry in this four-element model. Sensitization effect of SNP was correlated with ex-vivo PRN effects measured by flow cytometry, and included the expression of CD2, CD3, CD4, CD8, CD10, CD19, PGP, MRP1, LRP, bcl-2, p53 and function of transmembrane mitochondrial potential, before and after in vitro prednisolone exposure. Results: SNP caused itself (11%, p<0.01) and increased PRN (5-fold, p<0.001) cytotoxicity in patients lymphoblasts, but not in CCFR-CEM and NMC. Cytotoxic effect was 3.5-fold higher in T-ALL than in common-ALL samples. SNP additively increased sub-G1 phase and early apoptosis caused by PRN in all tested cells. SNP and PRN caused cell cycle arrest in G1 phase in patient lymphoblasts (p<0.01) and in CCRF-CEM cells (p<0.05). Both drugs neither separately not in combination caused cell cycle arrest in NMC. The effect of SNP sensitization correlated with upregulation of CD4 (p=0.041) and CD8 (p=0.034) expression, and loss of transmembrane mitochondrial potential (p=0.018) in leukemic cells after ex vivo prednisolone exposure. In conclusion, SNP induced growth suppression, apoptosis, increased prednisolone cytotoxicity and caused cell cycle arrest in lymphoblasts, but not in normal marrow cells. The dithiol ligand diamide induces mitochondrial membrane depolarisation and apoptosis. These processes can be inhibited by monothiol ligands, implicating dithiol oxidation in the apoptotic process. Dithiol oxidation also modulates key enzymes responsible for the cell's anti-oxidant defences. The dithiol-reducing enzyme thioredoxin normally maintains the reduced state of these enzymes. We therefore addressed the question of whether AW464 -a novel thioredoxin inhibitor -as well as dithiol ligands diamide and phenylarsine oxide are able to induce and execute a regular apoptotic sequence of events without overwhelming the cell's ability to detoxify reactive oxygen. All three agents were found to induce bak activation, cytochrome C release from mitochondria,mitochondrial membrane depolarisation, nuclear fragmentation, phosphatidyl serine exposure and Tdtsensitive DNA nicks. At the onset of apoptosis there was no evidence of increases in oxygen free radicals or peroxide in cells treated with AW464 or diamide. Phenylarsine oxide induced both free radicals and hydrogen peroxide. Early (8hr) apoptosis induced by all 3 agents occurred largely in quiescent cells (as detected by TUNEL), but by 24 hours an increased proportion of cycling cells were apoptotic after AW464 and diamide treatment. AW464 is under investigation as a novel chemotherapeutic agent, and the current study shows that this agent induces a well-orchestrated apoptotic programme. Breast cancer resistance protein (BCRP) has been detected in primitive normal haematopoietic cells and in samples from patients with AML. Lysotracker Green (LG) is a fluorophore linked to a weak base designed for the detection of lysosomes. It is effluxed by BCRP but not by p-glycoprotein or MRP1. Using 1 micromolar LG, we determined the modulation of LG retention by 5 micromolar GF120918 for 75 minutes in CD133+ve haematopoietic cells from donor stem cell harvests. Fluorescence from cells incubated at 4degreesC was subtracted from fluorescence at 37degreesC before calculating the ratio of fluorescence with modulator to fluorescence with solvent control. In CD133+ve cells from three healthy donors, the ratios were 1.44, 1.55 and 1.57 (compared with 0.99, 0.89 and 0.83 respectively in unselected mononuclear cells). In blast (CD45perCP low) cells from primary AML samples, ratios ranged from 0.73 to 2.3 (median 1.33). Ratios for daunorubicin modulation by GF120918 in AML samples did not correlate with those for LG modulation in the samples as a whole, but significant correlation was observed in p-glycoprotein negative samples (p=0.02). In those AML samples in which a proportion of cells expressed CD133, LG modulation was greater in the CD133+ve than in the CD133-ve subsets. Preliminary reproducibility data on repeat samples are encouraging. We conclude that Lysotracker Green is a sensitive probe for flow cytometric measurement of BCRPmediated efflux in normal and leukaemic haematopoietic cells. The study of LG modulation in AML patients is on-going. Comparisons of LG modulation ratios in fresh versus frozen samples and inter-laboratory studies are also in progress. L-Asparaginase is an effective drug for treatment of children with newly diagnosed acute lymphoblastic leukemia (ALL). The effectiveness of this drug results from a rapid and complete depletion of asparagine in cells. Leukemic cells are thought to be asparagine synthetase (AS) deficient and thereby incapable to re-synthesize asparagine out of aspartic acid. Asparagine deficiency impairs protein synthesis and finally results into cell death via apoptosis. In studies with human leukemic cell lines, resistance to LAsparaginase was shown to be associated with the capacity of resistant cells to upregulate the expression of AS. In the present study, we monitored the expression levels of AS during an in vivo exposure to pegylated L-asparaginase (PEG-ASP) as a single drug used in an upfront therapeutic window in children with ALL at initial diagnosis. AS mRNA levels in samples purified towards > 95% leukemic cells were detected by real-time quantitative PCR. In almost all 30 patients included so far , an increase in the expression of AS mRNA during PEG-ASP administration. The increase in AS mRNA was not associated with the clinical response to PEG-ASP. No differences were observed in AS mRNA levels between 20 clinically good responders (defined by < 1000 leukemic cells per ∝l of peripheral blood after 5 days of treatment), 6 intermediate (blasts between 1000/∝l and 10.000/∝l) and 4 poor responders ( blasts > 10.000/∝l). Remarkably, the expression of AS did not alter in one extremely poor responder with growing numbers of leukemic cells during PEG-ASP treatment. In addition no relationship was found between the in vitro responsiveness to PEG-ASP and basal or drug-induced AS mRNA levels in these patients. In conclusion, our data show that an increase in AS expression is not associated with an unfavorable response to PEG-ASP in children with ALL. The use of the antifolate methotrexate (MTX) plays an important role in the treatment of acute lymphoblastic childhood leukemia (ALL). Recently, the Breast Cancer Resistance Protein (ABCG2/MXR) was reported to confer cellular resistance to MTX. This observation opens the possibility of a role for BCRP in the homeostasis of natural folates as well. In theory, BCRP mediated transport of cellular folates might competitively inhibit MTX efflux, and thus influence cellular sensitivity to MTX. In this study we report effects of differences in cellular folate status on the transport activity of BCRP. We measured the cellular efflux of the BCRP substrate Hoechst 33342 in the human myeloid cell line RPMI 8226(s) and its mitoxantrone resistant and BCRP overexpressing subline 8226/MR. A new method was developed by which the cellular efflux of fluorescent compounds from suspension cells can be monitored online. This method uses a two-compartment cuvette system, divided by a semi-permeable membrane, and can be used with a relatively small amount of cells (~ 50.000 Treatment results in childhood acute leukemia improved markedly during the past 20 years. However, approximately 20% of the children with acute lymphoblastic leukemia (ALL) relapse and can not be cured with modern therapy. The major cause of treatment failure in childhood acute leukemia is the emergence of multidrug resistance (MDR). Several mechanisms of resistance are known but the best studied is the overexpression of P-glycoprotein (P-gp), a transmembrane protein encoded by the MDR1 gene. Different methods such as flow cytometry and immunocytochemistry can be used to analyze P-gp expression in clinical samples. However, controversy remains because these methods are semi quantitative. In this study, we developed a quantitative real-time RT-PCR to measure the amount of MDR1 transcripts. The primers and the TaqMan probe were designed using Primer Express Software (Applied Biostems). Glyceraldehyde 3-phosphate dehydrogenase and ubiquitin C were used as housekeeping genes in order to normalize the MDR1 data. The mRNA from the cell line K562/VLB20 which expresses P-gp, was used to develop the standard curves. All reactions were performed using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). Twenty-nine normal blood or bone marrow samples were included to determine the cut off value for MDR1 overexpression. Finally, the MDR1 status from 33 ALL patients at diagnosis and 9 patients at relapse, admitted to the department from June 1996 to January 2000, was determined. MDR1 overexpression could only be found in 4 newly diagnosed patients and one child at relapse. None of the 4 patients at diagnosis with high MDR1 expression relapsed. In contrast, 5/33 newly diagnosed patients with normal MDR1 expression suffered from a relapse. The relapsed child with high MDR1 expression is still alive, but 3/9 relapsed patients with normal MDR1 expression died. The MDR1 expression level determined by quantitative real-time RT-PCR did not correlate with outcome. In addition, the MDR1 concentrations at relapse were not higher than those at onset. These results are consistent with previous reports. However, in these studies other detection techniques were used, making it almost impossible to compare the results. Further investigations are necessary to elucida MDR in children with ALL. The aim of this study was the comparison of a sensitivity of tumor cells in vitro and clinical results at the patients with B-CLL. We have investigated 15 patients (6 males, 9 females) with B-CLL had Rai II-IV stage (II st.-11pts, III st.-2, IV-2). 5 pts were pretreated with cyclophosphaide, antracycline agents and prednisone, 10 pts were untreated. We have treated all pts with chlorambucil (Chl). Induction therapy has not exceeded for 3 months and maintenance therapy has continued for 4 months. Pts were treated until maximal response or prohibitive toxicity. Total dose made up 300 mg (range 120-400 mg) on the average for each patient. We assessed the sensitivity of CLL-cells from peripheral blood to Chl (0,4 mkg/ml) by &#1052;&#1058;&#1058;-assay on LD-50. All patients were evaluated for response according to NCL Working Group Criteria: 2/15-achieved complete remission (CR)-13,3%, 5/15-achieved partial remission (PR)-33,3%. CLL-cells these pts were sensitivity by MTT-assay to Chl on LD-50. 1/15 pts (6,7%) did not receive clinical response, more then 50% these CLL-cells were living with Chl at the MTT-assay. 7/15 pts received unimportance clinical effect, that conformed to MTT-results ( quantity living in vitro CLL-cells was near at 50% with Chl). Our data suggests that there is relationship between clinical response and results of MTT-assay. Response to glucocorticoids both in vivo and in vitro is a prognostic factor in childhood acute lymphoblastic leukaemia (ALL). An understanding of the determinants of sensitivity to glucocorticoids may lead to improvements in treatment. The influence of micro-environment as a modulator of response to glucocorticoids has not been studied despite the fact that disease in sanctuary sights (e.g. testis or cerebro-spinal fluid) is less responsive to systemic chemotherapy. Growth of cells in serum poor environments is associated with increased production of molecules that are involved in maintaining redox homeostasis, for example glutathione. Using the CCRF CEM C7 cell line, this study investigated the effect of culture in serum-free medium on prednisolone sensitivity and examined associated changes in glutathione homeostasis The steroid sensitive T lymphoblastic leukaemia cell line CCRF CEM C7(21d) was used. Cells were grown in RPMI 1640 with supplemental insulin/transferrin/selenite and antibiotics ± 10% foetal calf serum (FCS). Glutathione was measured using the modified recycling assay of Tietze. In vitro cytotoxicity was assessed using the colorimetric sulforhodamine B (SRB) assay. Cell cycle was evaluated by flow cytometric analysis of propidium iodide stained cells Serum deprivation resulted in lack of in vitro response to prednisolone. Sensitivity was restored on return to culture with 10% FCS. A greater than 2-fold increase in intracellular GSH levels (36.7 ± 0.07 vs. 17.4 ± 1.9 nmols/mg protein) was observed in serum-deprived cells. No change in cell cycle distribution was demonstrated. Glutathione depletion by addition of concentrations greater than 125µM BSO to serum-deprived cells partially reversed prednisolone resistance (0% to 20% cell kill). Moreover, on return to serum, the augmented response to prednisolone was observed with maximal effect at 125mM prednisolone, where addition of BSO at concentrations above 125mM resulted in an increase in cell kill from 43% to 67%. Serum deprivation in leukaemic cells induced steroid resistance and there was associated elevation in GSH. Depletion of GSH by BSO was shown to partially rest steroid resistance. Such a mechanism may be operative in sanctuary sites for ALL. ore steroid sensitivity, suggesting a more direct role for GSH in inducing The Sydney Cancer Center, SYDNEY, Australia Infant (i.e. children 12 months of age or younger) ALL is characterized by a high incidence of MLL gene rearrangements, a poor outcome and resistance to important chemotherapeutic drugs. One exception is cytosine arabinoside (Ara-C), to which infant ALL cells are highly sensitive. To date, the mechanisms underlying drug resistance in infant ALL remain unknown. Possibly, multidrug resistance (MDR) proteins like P-glycoprotein, encoded by the MDR1 gene, multidrug resistance associated protein (MRP1), lung resistance-related protein or major vault protein (LRP/MVP), and the recently discovered breast cancer resistance protein (BCRP), play a role. Therefore we measured the mRNA levels of these proteins in infants (n=13) and non-infants (n=13) with ALL, using realtime quantitative RT-PCR. The mRNA expression levels of these MDR genes were correlated to the cytotoxicity of several chemotherapeutic drugs used in the treatment of ALL. Infants with ALL differed from non-infants in their BCRP mRNA expression, which was significantly 2.4-fold lower in infants (p=0.009). In addition, BCRP mRNA expression correlated with the cytotoxicity to Ara-C (Rs=0.53, p=0.012), to which infant ALL cells were 3.7-fold more sensitive compared to non-infants with ALL. (p=0.051, MTT-assay). For MDR1, MRP1 and LRP/MVP, no significant differences were observed between both groups. Furthermore, no posititve correlation was found between MDR1, MRP1 and LRP/MVP expression and the cytotoxicitiy of the drugs tested. These findings suggest that Ara-C might be a substrate for BCRP, and that Ara-C sensitivity in leukemic cells from infants with ALL may be explained by a decreased efflux of Ara-C out of these cells, mediated by BCRP. However, culturing leukemic cells from ALL patients in the presence of the specific BCRP inhibitor Ko143 had no effect on Ara-C cytotoxicity. In addition, inhibiting Bcrp1 in the Mdr1a, Mdr1b and Mrp1 deficient mouse cell line Mef3.8 and the Bcrp1 overexpressing subline Mef3.8/T6400, also did not modulate Ara-C cytotoxicity in these cells, whereas it did modulate the cytotoxicity to mitoxantrone, a known substrate for Bcrp1. Therefore we conclude that Ara-C is not a substrate for BCRP and that MDR proteins do not play a significant role in drug resistance in infant ALL. Expression levels of several apoptosis regulating proteins including Bax, Bcl-2, Bcl-xL, Mcl-1, the main effector of apoptosis (pro-)caspase-3 and the caspase inhibiting proteins c-IAP1, c-IAP2 and XIAP were investigated in 60 initial acute lymphoblastic leukemia (iALL), 21 relapsed ALL (rALL) and 19 initial acute myeloid leukemia (iAML) samples and were correlated with in vitro glucocorticoid (GC) resistance (MTT-assay). Cell death regulator expression was determined by Western Blotting. In iALL, correlations were found between expression levels of Bcl-2 and Bax, Bcl-xL and Bax, Bcl-xL and Mcl-1, procaspase3 and Bax, pro-caspase3 and c-IAP1, c-IAP1 and Bax (r = 0.35-0.41, p < 0.05). rALL, compared to iALL, expressed 1.5-fold higher levels of bcl2 and mcl1 and 1.3-fold higher Bcl-2/Bax ratios (p < 0.05). AML samples, compared to iALL, expressed 1.4 fold higher levels of Bax, 2.1-fold higher levels of Mcl-1, 2.1-fold higher levels of pro-caspase3 and 2.2-fold lower levels of c-IAP2 (p < 0.05). In iALL GC resistance correlated with elevated expression of c-IAP2 and XIAP (r = 0.35 and r = 0.44; p < 0.05) and in rALL with increased Bcl-2/Bax ratios and low pro-caspase3 (r = 0.64 and r = -0.66; p < 0.01). Altogether these results show a leukemia subtype specific expression profile of the cell death regulators, and specific correlations with GC resistance in iALL (c-IAP2/XIAP expression) and rALL (increased Bcl-2/Bax ratios, low pro-caspase3). The aim of the present study was to contribute to a more rationalized use of glucocorticoids (GCs) in pediatric acute myeloid leukemia (AML) by studying the relationship between in vitro GC responsiveness of AML cells, cell biological features and prognosis in 117 pediatric AML patients treated with GC containing protocols (AML-BFM-87/93, DSCLG-ANLL 87/93). In vitro GC resistance and GC-induced proliferation were determined by MTT assay, GC-induced differentiation by morphology. Resistance to prednisolone (PRD) was expressed as the LC50 value. Fifteen percent of all samples were relatively sensitive (LC50 < 150 µg/ml) to GCs, with an over-representation of FAB type M1 (6/14 M1 samples were sensitive versus 11/101 of non-M1 samples; p=0.002). However, none of the samples was highly sensitive (LC50 < 0.1µg/ml). GC-induced cell proliferation was observed in 26% of the samples, most frequently in M5 (50% of all M5 samples; p = 0.01). In vitro GC resistance did not correlate with survival. Patients whose blasts proliferated in vitro upon GC exposure, had a lower 5-year relapse free survival (35 +/-13% versus 60 +/-7%, p=0.03). This difference was retained after the exclusion of the M5 patients. GC-induced differentiation was not observed in vitro. Based on these results we suggest that it may be better to exclude glucocorticoids from contemporary AML treatment protocols. Although glucocorticoids (GC) are extensively used in the treatment of ALL, the cellular mechanisms underlying GC resistance are still unknown. In the present study we investigated whether the expression level of hGR or its splice variants (hGR-alpha, the active splice variant and hGR-beta and hGR-P) at diagnosis or upon GC exposure are related to GC resistance in childhood ALL. In 2 patient groups we studied the basal expression levels of the hGR splice variants. 12 Children with leukemic cells in vitro sensitive to prednisolone were matched each with a patient with in vitro resistant leukemic cells. In a second patient group, 10 patients with an in vivo prednisone poor response were matched each with 2 patients with a prednisone good response. (Matched according to age, gender, immunophenotype and white blood cell count at diagnosis.) RNA expression levels of the hGR splice variants were measured using a quantitative real-time RT-PCR (taqman) assay and standardized to GAPDH. In both patient groups no differences were found in the expression levels of hGR (i.e. the sum of the measured hGR-alpha, hGR-beta and hGR-P levels) of its 3 splice variants between the matched sensitive and resistant patients. To study the ability to regulate the hGR expression level, 4 children with leukemic cells in vitro sensitive to prednisolone were matched each with a patient with in vitro resistant leukemic cells. Leukemic cells were incubated with prednisolone at a concentration of 250 ug/ul for 3, 8, 24 and 48 hours. In the first 24 hours, an upregulation of the hGR and its splice variants was observed in 7 out of 8 patients (ranging from 2-30 fold). However, no differences in regulation of the hGR splice variants were found between the in vitro sensitive and resistant patients. We conclude that neither the basal expression level of the hGR or the 3 splice variants (hGR-alpha, hGR-beta and hGR-P), nor the ability to (up) regulate the hGR or its splice variants is related to GC resistance in childhood ALL. The aim of the research was to learn capabilities of prediction leukemic cells in vitro to chemotherapy drugs resistance before their application in vivo and comparison of the obtained data to clinical effect of program, used in childhood acute leukemia (AL) treatment. The definition of leukemi&#1089; cells sensitivity in vitro was conducted by the MTT-test and DISC-assay. The selection of a method was determined by the number of blast cells in bone marrow. We used the DISC-method for patients (pts) with low leucocytosis and low leukemi&#1089; cells in punctate of bone marrow (less than 50%). We studied 24 pts with childhood acute limphoblastic leukemia (ALL), 4 of them had a relapse of the disease; there were 11 pts with AML (2-with the relapse). For an estimation of the obtained results the pts with ALL and AML are divided into 2 groups: the favourable and unfavorable prognosis. The pts with standard and average risk, fixed by to BFM criteria, who achieved the remission by 33 day, were included in favourable group of ALL. In group of the unfavorable prognosis were included pts with high risk group and with disease relapse. The patients with AML were arranged on 2 groups according to morphological, immunophenotype and cytogenetic data. The ALL cells were high sensitive to vincristine (&#1088;=0,018), Ara-C (p=0,034), methotrexate (&#1088;=0,004) in favourable prognosis group. Blast cells of pts, resistant to induction therapy, were insensitive in vitro to all drugs. A majority of pts with ALL relapse was resistant to all investigated drugs except for vp-16. the results of the sensitivity to vincristine (&#1088;=0,008), methotrexate (&#1088;=0,020), daunorubicin (&#1088;= 0,03), doxorubicin (&#1088;=0,001) were statistically adequacy between two groups of pts. The expression of myeloid antigens CD13, CD33, CD11b in ALL was accompanied by lower sensitivity to drugs in vitro. Expression BCL2 is detected on biphenotype ALL cells and in 33 % of AML pts from unfavorable prognosis group. The BAX positive expression was detected in 44 % of ALL pts with favourable prognosis. There was no BAX expression in AML pts. The &#1050;i67 expression in AL was not observed. Thiopurine S-methyltransferase (TPMT) catalysis the S-methylation of thiopurine drugs such as 6-mercaptopurine (6MP) and azathioprine (AZA). Thiopurines are generally used to treat acute lymphoblastic leukemia (ALL), rheumatoid arthritis and autoimmune diseases. They are also used as an immune-suppressant after transplantation. Cytochrome p450 3A (CYP3A) enzymes are responsible for the metabolism of over 50% of all clinically used drugs. Polymorphisms in the metabolizing genes can cause abolished, reduced, altered or increased enzyme activity of the enzyme products. Variations in expression levels of these enzymes are affect whether patients will have a positive or adverse drug response. The molecular basis for the genetic polymorphism of TPMT (*2, *3A, *3B and 3C), CYP3A4*1B and CYP3A5*3 have been established for several populations. In the current study, we determined these genotypes in 148 individuals with Turkish origin. Turkish population TPMT*2, *3A, *3C allele frequencies (0.2%, 0.1% and 0.13% respectively) were similar in Americans-Caucasians. TPMT*3B was not detected in Caucasians, Asians and American-African as well as our population. Also we have found the CYP3A4*1B (n=148) allele frequency 1.3% (148/4). CYP3A4*1B allele frequency was low compared with African-Americans, Caucasians and Asians. The data on polymorphic distribution of CYP3A5*3 allele is not available for many populations. The CYP3A5*3 allele frequency was found 15% (93/14) in our population. These data indicate that the similar TPMT and CYP3A mutant alleles are found in white populations, but that the predominant mutant alleles differ among different ethnic groups. This study provides the first analysis of the allele frequency distribution of TPMT (*2, *3A, *3B and *3C), CYP3A4*1B and CYP3A5*3 genes in Turkey. Identification of the variant TPMT, CYP3A4*1B and CYP3A5*3 genotypes would be useful tool to avoid severe hematological toxicity of known anticancer agents, immune-suppressor drugs and other common drug adverse affects in Turkish patients. Risk-adapted therapy in acute lymphoblastic leukemia (ALL) of childhood relies on traditional risk factors such as age, white blood cell count, immunological subtype, chromosomal aberrations and response to treatment. The aim of this study is to compare between in vitro cellular drug resistance and these prognostic factors. METHOD: We performed in vitro test at bone marrow samples in 120 children with Acute Lymphoblastic Leukemia using the MTT assay. We evaluated 8 drugs (VCR, DNR, PRED, L-ASP, DEXA, ADR, IDA, ETO) for test. and calculated the 50% lethal concentration (LC 50). Dose-response curves were constructed to determine the LC 50, the drug concentration lethal to 50% of the leukemic cells. Nonparametrically distributed median LC 50 values were analysed with the MannWhitney U test.. RESULTS: The patients older than 10 years had a 3.2 fold higher; and those younger than 2 years had a 5 fold higher in-vitro drug resistance to prednisolone when compared to the patients between 2 and 9 years. In comparison to the cases whose leukocyte counts were >50000, the cases with < 50000 leukocytes were 1,61 fold more resistant to Prednisolone (p <0.01); 1.99 fold more resistant to DEXA; 2.05 fold more resistant to ARA-C; and 1.8 fold more resistant to IDA. Patients with CD34 positivity were 1.7 fold more resistant to ARA-C than CD34 negative patients. The patients with t (9,22) translocation were 2,4 times more resistant to prednisolone, 3,6 times more resistant to DEXA, 1,8 times more resistant to ARA-C, and 3,6 times more resistant to IDA when compared to the cases without t(9,22) translocation. Patients who were non-responsive to chemotherapy at 14th day bone marrow aspiration had an in-vitro drug resistance greater 2,1 times for ADR, 4,8 times for VCR, 1,6 times for prednisolone, and 2,3 times for IDA when compared to responders. CONCLUSION: Cellular drug resistance, evaluated with LD50-drug resistance percentile curves, seems to be associated with adverse prognostic factors, and it may be a parameter for risk-adapted therapy. Deoxycytidine kinase (dCK) is responsible for the activation of several clinically important anticancer agents. These nucleoside analogs are widely used for the treatment of malignancies and are dependent on phosphorylation by dCK. To determine the expression level of dCK protein in pediatric malignancies we have set up an immunocytochemical method, using a rabbit-anti human dCK antibody. Immunocytochemical staining was performed on cryopreserved cytospins of 50 acute myeloid leukemia (AML), 52 acute lymphoblastic leukemia (ALL), 10 retinoblastoma and 12 brain tumor samples. The leukemic cell lines U937 and CCRF-CEM were used as positive controls. Negative controls were performed by omitting the first antibody. dCK protein expression was determined by scoring the intensity of the staining: negative (0), low (1+), intermediate (2+), high (3+), or very high (4+), by two independent investigators. In the leukemic cell lines U937 and CCRF-CEM and in the different tumor types a predominantly cytoplasmic staining was observed. In 4 out of 31 AML samples and in 2 out of 29 ALL samples we also observed staining in the nucleus. The AML and retinoblastoma samples showed an intermediate to (very) high expression of dCK. The expression level of dCK in ALL samples ranged from low to (very) high. In contrast, the majority of brain tumor samples expressed low to intermediate levels, with 2 samples expressing no dCK. The interobserver variability between two observers showed agreement in 72/82 (88%) cases (kappa = 0.81). On Western blotting the antibody detected dCK appropriately at 30 kD, without additional bands. In conclusion, immunocytochemistry is an effective method to determine the expression level of dCK in patient samples. In the vast majority of samples dCK was located exclusively in the cytoplasm. It was possible to discriminate between patient samples with a low, intermediate and (very) high expression level of dCK. There were clear differences in dCK expression observed between tumor types. The overall prognosis of childhood acute myeloid leukemia (AML) has improved considerably in the past decades. Curative treatment however remains problematic, since the survival rate for children with newly diagnosed AML of approximately 50-60%. Drug resistance of the leukemic cells is a major factor underlying treatment failures. Cytarabine is an important drug in the treatment of childhood AML. Resistance to this drug (either intrinsic or acquired) is therefore a clinically relevant problem. In this study we determined cross resistance to cytarabine of 11 different cytostatic drugs, in 58 AML samples taken at initial diagnosis. In order to study these cross resistance patterns appropriately we selected a cohort of patient samples in which all drugs were successfully tested. Drug resistance was determined with the 4 day total cell kill MTT assay. Resistance was expressed as LC50 values, the drug concentration lethal to 50% of the cells. The following drugs were tested: cytarabine, cladribine, daunorubicin, decitabine, etoposide, fludarabine, gemcitabine, L-asparaginase, 6-thioguanine and vincristine. Correlations were determined by Spearman's rank correlation (rho). We observed cross resistance between cytarabine and all other drugs tested: cladribine (rho=0.60, p<0.0001), fludarabine (rho=0.40, p=0.002), gemcitabine (rho=0.65, p<0.0001), decitabine (rho=0.38, p=0.003), 6-thioguanine (rho=0.39, p=0.002), daunorubicin (rho=0.30, p=0.02), etoposide (rho=0.47, p<0.0001), Laparaginase (rho=0.48, p<0.0001), and vincristine (rho=0.40, p=0.002). From these compounds the agents acting similary (e.g. deoxynucleoside analogs) showed the highest correlation, while also for other DNA interacting agents a high cross-resistance was observed.
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In conclusion, we observed cross-resistance between cytarabine and several different classes of anti-cancer agents. These findings indicate that a downstream cell death regulating pathway may be the major determinant of resistance to anticancer agents in pediatric AML. Determination of molecular/cellular predictors of tumour sensitivity to anticancer chemotherapy is one of the most attractive approaches in order to improve outcome of current treatments. In our experiments we identified new cytogenetic factors, which predict responsiveness of tumour cells to 'anticancer drugs under in vitro conditions. We evaluated drug resistance in 52 human cancer cell lines against 28 anticancer drugs with different mechanism of action and/or resistance by MTT assay. In parallel we have examined status of selected genes previously shown to associate with drug sensitivity and/or patient's prognosis; Iler-2/neu, TOP2A, C-MYC. Cyclin D1, TP53 and copies of chromosomes 11 and 17 using the FISH technique. Relationships between individual drug sensitivity and genetic status of tumour cells were established by Spearman correlation analysis. Our data confirmed previously published association between TOP2A status and sensitivity against topoisomerase II inhibitor, doxorubicin. However, we have also identified new correlations: T58 status versus sensitivity to 6-thionguanine, cladribine and dacarbazine; Cyclin D1/chromosome 11 ratio and sensitivity to carboplatin; lower sensitivity to 6-thioguaninc in Cyclin D1 amplified cells. We have also found that cells with polypIoidy nf chromosome 11 tend to be more sensitive to prednisolone and dexamethasone. Rationale for those observations is either based on direct involvement of examined genes and/or co-localization with neighboring genes involved in the mechanism of drug action/resistance. We expect that confirmation of our findings in primary tumour cells in correlation with clinical response to therapy will provide rationale for precise tailoring of anticancer chemotherapy in the future. 
P39 IN VITRO CHEMOSENSITIVITY AND GENETIC STATUS OF SELECTED ONCOGENES IN TUMOUR CELL LINES
BFM-Study Group, MUNSTER, Germany
Cytarabine is an important drug in the treatment of childhood acute myeloid leukemia (AML) and high-risk acute lymphoblastic leukemia. Resistance to this drug (either intrinsic or acquired) is therefore a clinically relevant problem. To modulate cytarabine resistance ex vivo we combined cytarabine with 6 potential resistance modifiers: the nucleoside analogs cladribine and gemcitabine, the hypomethylating agent decitabine, aphidicolin (inhibitor of DNA polymerases alpha, delta and epsilon), and flavopiridol and UCN01 (inhibitors of cyclindependent kinases). The single agents and their combinations were studied ex vivo in blast cells isolated from 10 children with de novo AML using the 4 day total cell kill MTT assay. Cytarabine was tested in 6 different concentrations, the modulators were tested at a low concentration (inducing on average 10% cell kill as a single agent) and a high concentration (inducing on average 30% cell kill as a single agent). The ex vivo interactions of cytarabine in combination with the different modulators were investigated by computer-assisted analysis using the Calcusyn software, based on the median drug effect method developed by Chou and Talalay, by calculation of the combination index ((CI); additive +/-1; synergistic <1 and antagonistic >1). Co-incubation of cytarabine with aphidicolin, in both the low and the high concentration, showed strong synergism (median CI= 0.28 and CI=0.18 respectively, (n=9)). The combinations of cytarabine/cladribine (median CI= 0.82 and CI=0.51 (n=10)) and cytarabine/gemcitabine (median CI= 0.5 and CI=0.5 (=10)) were all synergistic. Nearly additive and moderately synergistic interactions were observed between cytarabine/flavopiridol (median CI=0.93 (n=10) and CI= 0.82 (n=8)) and cytarabine/UCN01 (median CI= 0.82 and CI=0.74 (n=9)). However, the combination of cytarabine with decitabine was antagonistic (median CI>10 (n=6) and CI=5.92 (n=3)). In conclusion, additive or synergistic interactions of cytarabine with aphidicolin, cladribine, gemcitabine, flavopiridol and UCN01 were observed in this ex vivo model testing pediatric AML samples, supporting the future evaluation of these combinations in clinical trials with AML patients. Previously, it has been shown that expression of GST-pi was significantly higher in AML compared to ALL patients. Little is known about the role of this protein in drug resistance and evolution of disease in childhood acute myeloid leukemia. Topoisomerase II alpha is an intracellular target for antracyclines; its decreased levels were associated with multidrug resistance in cell lines. Expression of Topoisomerase II alpha and Glutathione S-Transferase-pi was studied in childhood acute myeloid leukemia by immunocytochemistry. In vitro cytotoxicity of daunrubicin (DNR), etoposide (VP-16), prednisolone (PRD) and ifosfamide (IFOS) was measured by the MTT assay. The expression of proteins was measured in blast cells of bone marrow or peripheral blood from 96 patients with AML (75 with initial disease, 18 relapses and 3 with AML as a secondary disease). The results were correlated to risk factors such as age, FAB classification, Auer rods, white blood count. Result showed that: 1.Decreased levels of TOPO II were observed in 29/96 patients (30%). 2.High expression of GST-pi was detected in 56/96 patients (58%). 3.Expression levels of both proteins were not related to the degree of resistance to DNR, VP-16, PRD nor IFOS. 4.TOPO II and GST-pi expression did not differ between untreated and relapsed patients. In conclusion high expression of GST-pi and decreased levels of TOPO II are not correlated with in vitro resistance to DNR, VP-16, PRD or IFOS nor with clinical risk factors in childhood acute myeloid leukemia. The MTT assay is frequently used for chemosensitivity testing in ALL. However, in order to obtain a sufficiently high signal, we have found that 1-5 x 10^5 blast cells per well are required. The ViaLight HS assay on the other hand is a very sensitive technique providing strong readings with only 1-5 x 10^4 blasts per well. As we wished to increase the number of drugs in our chemosensitivity profile we decided to compare chemosensitivity results using the two methodologies.
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Blast cells were isolated from 42 children with ALL. As has been previously reported for the MTT assay, there was a strong relationship between number of live ALL blasts and, in this case, intracellular ATP content (r^2=0.999). The MTT assay was used for chemosensitivity testing in 14 patients, the ATP assay in 22 patients and sufficient blasts were isolated from 6 patients to carry out both MTT and ATP assays. The success rate for the ATP assay was 100% compared to 85% for the MTT assay and the mean number of drugs tested by ATP was higher at 15 compared to 7 for the MTT assay. There was a marked variation in drug effect between patients using both MTT and ATP end points. As is found for the MTT assay, there was a significant increase in LC50 values (drug concentration lethal to 50% of cells) in patients who had received previous chemotherapy using the ATP assay (p=0.04). Where both methods were used, it was possible to make 36 drug comparisons. There was a significant correlation between the results from the two assays (r^2=0.93). However, results obtained using the ATP assay were on average 23% lower (p=0.009) than those from the MTT assay.
Although more expensive, we have found the ViaLight HS ATP assay to be a simple reliable technique, allowing accurate chemosensitivity measurements when few blast cells are obtained. However, as results are significantly lower than those obtained using the MTT assay, we intend to compare these results with clinical outcome before using it routinely to predict drug resistance in the clinic. The bisdioxopiperazine razoxane and its enantiomer, dexrazoxane have a multiplicity of biological and clinical effects. They have shown promise in cardioprotection, as an inhibitor of angiogenesis and in the treatment of various diverse conditions such as psoriasis and cancer, where dexrazoxane has been shown to delay the emergence of drug resistance (Hellmann, BMJ, 1999; Sargent et al, Br J Cancer, 2001) . It is reasonable to propose that there must be a mechanism(s) of action that is common to these wide-ranging effects. The aim of this study was to elucidate possible common actions such as a deceleration of cellular proliferation, by studying the effect of dexrazoxane on 1) the cell cycle and 2) intracellular ATP levels. The effect of dexrazoxane on the cell cycle of the human leukaemia line K562, was assessed using propidium iodide staining and flow cytometry. Expression of the cell cycle control gene, CDK1, which is involved in the G2/M transition was also measured in these cells using immunofluorescence with the SC54 monoclonal antibody. Intracellular ADP/ATP ratios were assessed after incubation in dexrazoxane. Incubation in IC50 levels of dexrazoxane (70uM) led to G2/M arrest within 8 hours. At 24 hours 35+/-6% of cells had tetraploid or higher DNA content, suggesting DNA re-replication. CDK1 protein expression was measured after 24 hours incubation in 70uM dexrazoxane and levels were reduced to 45+/-15% of that found for control cells. Our results, therefore, suggest that these cells are undergoing two or more S-phases without intervening mitoses, so delaying cellular proliferation. After 24 hours, there was a 48+/-12% reduction in ADP/ATP ratio compared to control suggesting a block in ATP hydrolysis. This block appeared to be concentration dependent: Our results suggest that both alterations in CDK1 and/or hydrolysis of ATP by dexrazoxane may be affecting cellular proliferation so leading to the multifaceted action of this interesting agent. Further studies of these observations are warranted to establish relationships between these factors. Immunotherapy holds promise as a strategy for the eradication of residual cells in acute myeloid leukaemia (AML). Leukaemic dendritic cells (DC) combine optimal antigen presentation and tumour antigenicity. We aimed at generating functionally competent AML-DC suitable for vaccination. AML-DC were cultured either in the presence of cytokines (GM-CSF, TNF-, Flt3-L, SCF, IL-3 and IL-4) or by the use of calcium ionophore (CI) and IL-4 (Westers et al., Cancer Immunol Immunother 2003, in press ). The two-week cytokine culture was successful in 64/85 patients as evidenced by the up-regulation of CD40, CD54, CD80, CD86, CD83 and HLA-DR and increased allogeneic T cell stimulating capacity. The rapid two-day culture method based on CI and IL-4 was feasible in 68/85 patients. In order to select optimal culture methods, we studied whether the cytokine receptor profile of AML blasts was predictive for the differentiation into AML-DC. Prior to culture, flowcytometric analysis of the expression of GM-CSFR, TNF -RI, TNF -RII, IFN -R, Flt3-LR, SCFR, IL-3R and IL-4R was performed. By multiple regression analysis, the preculture expression level of TNF -RI (n=30, mean% ± SD, 19.2±13.7; range: 1.0-56.6) was predictive for the expression of CD40 (p=0.009), CD54 (p=0.001) and CD86 (p=0.005) in the cytokine culture. After culture, TNF -RI + sorted cells showed a 5-15 fold increased expression of CD40 + /CD86 + AML-DC as compared to the corresponding TNF -RI -fraction. Alternatively, blasts with low TNF -RI expression could be differentiated into AML-DC, in 8/10 patients, by the CI method, which bypasses receptor mediated signalling. The quality of serum-free cultured AML-DC proved to be comparable to serumenriched culture indicating their feasibility for clinical purposes. Serum-free cultured AML-DC were used to stimulate autologous T cells of 13 patients in vitro. T cells were predominantly skewed towards a Th1 cytokine profile (IFN ) and showed cytolytic capacity towards corresponding autologous blasts in 9/13 patients as assessed by flowcytometry. In conclusion, TNF -RI expression on AML blasts predicts cytokine-induced differentiation into AML-DC. Serum-free cultured AML-DC are capable of inducing an autologous anti-leukaemic response, demonstrating the applicability for translation into clinical vaccination protocols for AML patients. The aim: The study of the efficacy of CD34+ cells mobilization in dependance on the number granulocytes, lymphocytes and monocytes in pereferical blood prior to the beginning of the G-CSF course in children with various oncologocal and oncohaematological diseases and in apparently healthy donors. Methods: The evaluation of CD34+ cells number by flow cytometry, the evaluation of GM-CFU number in blood (PB) and borne marrow (BM) by clonogenic cultivation, the differential count of PB by automatic analyzer, morphological analysis of BM. Results: We revealed a reliable direct correlation between the number of granulocytes prior to the beginning of administration of GCSF and the number of CD34+ cells obtained resulting from mobilization, with the efficacy of CD34 mobilization not depending upon the baseline level of lymphocytes and monocytes. The efficacy of stem cells mobilization neither depends upon the main diagnosis and the initial lesion to the bone marrow. It was determined that reaching the necessary number of the CD34+ cells require less procedures of cytapheresis and shorter duration of using GCSF in groups with a greater number of granulocytes prior to the beginning of mobilization. In repeated session of cytapheresis a trend was noted toward a decrease in the number of the CD34+ cells harvested during one procedure of cytapheresis. Hence, the number of granulocytes at the moment of prescription of GCSF turned out the most important criterion for predicting the efficacy of peripheral stem cells mobilization. The percentage of septicemia according to the different diseases was 22% (41 cases) for AL and 20% (10 cases) for ML, respectively. The greatest percentage of septicemia was established in the subgroup of acute myelogenous leukemia (AML) -42% (10 cases). In 5 cases (10%) septicemia was detected prior to the onset of anticancer chemotherapy (ACCT). Gram-positive bacteremia was detected in 23 episodes (45%), gram-negative bacteremia in 25 episodes (49%) and fungemia in 3 episodes (6%). The predominant microorganism were coagulase-negative staphylococci (31%). Documented septicemia during ACCT were detected in 46 FE: 43% during induction, in 9% -during remission and 48% -during relapse. Septicemia was registered twice in children with more than one FE -in 27% (10 cases), and in 3% (one case) -three times. In 16 cases (35%) the septicemia was registered in the first FE, in 19 (41%) -in the second one, and in 11 cases (24%) -after the second episode. In 38 cases (83%) the septicemia was accompanied by damaged integrity of the mucosal and/or skin anatomic barriers, in 35 (76%) severe focal infections were documented: severe mucosites -22 (48%), pneumonia -18 (39%), cellulitis, infected sites of venous pumctures, skin abscesses and periproctites -16 (35%), enterocolitis -14 (30%). In 11 cases (23%) an isolated bacteremia without identification of focus infection was documented. The authors conclude that the percentage of septicemia is the highest in neutropenic children with AML. The microbiological verification of coagulasenegative staphylococci is the most commonly met (31%). In 83% the septicemia was accompanied by damaged integrity of the mucosal and/or skin anatomic barriers, and in 76% severe focal organ involvement are documented. In this study we investigated the effects of radiotherapy on oxidative burst activity of patients with lymphoma. Oxidative NADPH activity of neutropfils of 9 patients with lymphoma, who were planed to get radiotherapy, were measured by fluorometry before radiotherapy, at the middle of radiotherapy and at the end of the radiotherapy. There was no significant difference between control group and patients who didn't get radioptherapy yet regarding NADPH oxidase activity of neutrophils (p>0.05). We found a significant increase in the activity of NADPH oxidase at the end and at the middle of radiotherapy compared to before radiotherapy (p<0.01). In this study we found that radiotherapy increased the oxidative burst.
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Gemtuzumab ozogamicin (GO) consists of an anti-CD33 antibody linked to the cytotoxic compound calicheamicin. After binding to CD33, GO is internalized and calicheamicin is released and causes DNA damage. CD33 is expressed on 90% of AML and 15% of ALL samples. We treated 15 children with AML (4 refractory to induction chemotherapy, 7 refractory to re-induction at relapse, and 4 at second or greater relapse), and 3 children with ALL (1 refractory to re-induction at relapse, 1 relapse whilst on treatment, and 1 multiple relapsed) with GO on compassionate use basis. Dosages varied form 4-9 mg/m2 and 1-3 infusions of GO were given. Eight of the 15 children with AML showed a bone marrow blast count <5%, in 3 of these 8 children there was hematological recovery, but platelet counts were <100x109/l (defined as CRp). No complete remissions occurred. In case of response hematological recovery was not awaited, and further therapy was given as soon as possible. Six of the 8 children were treated further with 1 autologous SCT, 3 MRD and 2 MUD SCT. To date, 2 children are alive with 6 and 9 months follow-up. Non-hematological toxicity consisted of grade 2 and 3 transient biochemical hepatotoxicity in 2 children, and grade 4 hepatotoxicity in another 2 children, consisting of VOD in one, and massive leukemic infiltration of the liver (biopsy) in the other. One child suffered from infusionrelated grade 3 hypotension.
In childhood ALL, in 1 child a CR was observed with full hematological regeneration, after which a MUD SCT was done. The child is alive 6 months after SCT. The 2 other children showed a clear drop in WBC after GO. In 1 child this was transient, and the other child (combined BM/CNS relapse) died of complications of CNS leukemia before further therapy could be given.
In conclusion, GO has clinical activity both in pediatric relapsed/refractory CD33 positive AML and ALL. Some children may be salvaged by intensive post-remission therapy following GO, although follow-up is still short. We are now expanding our experiences in AML in an ongoing I-BFM Study Group phase II trial.
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LACK OF RESPONSE TO MYLOTARG THERAPY IN A CHILD WITH RELAPSE OF ACUTE MYELOID LEUKAEMIA AFTER BONE MORROW TRANSPLANTATION
E Zielinska, A Charubczyk, J. Bodalski Medical University of Lodz, LODZ, Poland Mylotarg (gemtuzumab ozogamicin) recently was approved by the US Food and Drug Administration for the treatment of patients with CD33-positive acute myeloid leukaemia in first relapse, age 60 years or older, who are not considered candidates for other types of cytotoxic chemotherapy. Preliminary data in paediatric patients also suggest that the immunoconjugate have been reasonably well tolerated. We described lack response to Mylotarg therapy in 3 years old boy with relapse of acute myeloid CD33 positive leukaemia. According to FAB classification patient was classified as M5 leukaemia. When he was 19 months old he received first-line treatment polychemotherapy regimen according to the ANLL-98 programme for HR and then he was transplanted with allogeneic bone morrow. The relapse had occurred 9 months after hematopoietic stem cell transplantation and he received three courses therapy consisting of fludarabine, cytarabine, and idarubicine and granulocyte colony stimulating factor (G-CSF). After first [IDA-FLAG] the next two FLAG courses with idarubicine omitted was recommended because of toxicity reasons. The patient was nonresponder to this therapy. Mylotarg was introduced after all of contemporary chemotherapy regimens have been performed. After three doses of Mylotarg in dose 9mg/m2 we observed slightly increased levels of hepatic enzymes and myelosupression with 90% of blasts in bone marrow. Child's death occurred about one month after end of treatment with bleeding to CNS. Thus, the treatment with Mylotarg in the paediatric case of highly advanced AML was unsuccessful and has no positive response on the disease course. Radiotherapy, fludarabine, CD20 antibody and glucocorticoids can kill malignant lymphocytes in B-CLL and SLVL. To evaluate the relation of the number of CD20 molecules per cell and effect of radioconjugated and cold CD20 antibodies we compared CD20 expression in B-CLL and-SLVL and related this to apoptosis in response to 6 different cytotoxic treatments. Peripheral blood lymphocytes were isolated using Ficoll in 30 patients with CLL, and 4 with SLVL(differentiated on CD5, CD19, CD10, 79b, S Ig, CD24, CD23, CD103 and FMC7). Peak Channels were measured for CD20, CD19 and the complement decay accelerating factors (DAF) CD55 and CD59. Peak channels for CD20 were compared to FCRC beads (Bangs Lab) to evaluate the amount of CD20 receptors per cell. Cells were treated in vitro with (1)213Bi conjugated to anti-CD20 with CHX-A''-DTPA as a chelator (absorbed dose 2 Gy), (2)external 60Co gamma irradiated(2 Gy), (3)fludarabine 5mM, (4)methylprednisolone 10µM,(5)cold anti-CD20 (Mabthera) and human serum as a complement source or (6)cold anti-CD20 + gamma-radiation were intra individually compared with non treated cells. Samples were cultured for 24h. Annexin-V and 7-AAD were evaluated by flow cytometry to examine apoptosis. Total apoptosis was scored as excess apoptosis over the untreated samples. Results of apoptosis (mean+SD) are shown in the table, where comparisons of B-CLL vs SLVL were made by two-tailed T-test. Apoptosis(%) SLVL(n=4) B-CLL(n=30)T-test p Gamma-radiation 15.3+11.8 16.4+11.9 0.85 Fludarabine12.2+4.3 13.8+13.4 0.60 Prednisolone23.8+17 21.5+12.9 0.73 213Bianti-CD20 40.7+22.5 23.6+15 0.22 Cold antiCD2042.6+22.5 0+10 0.019 AntiCD20+gamma51.2+19 13.+17.4 0.025 Peak channel CD20:1177+551 116+78 7.4*10E-12 Peak channel CD19:170+90 91+42 0.005 In conclusion no differences were observed between CLL and SLVL in apoptosis induced by fludarabine, gamma radiation and prednisolone. Both cold and radioconjugated antiCD20 induced more apoptosis in SLVL than in B-CLL, due to the much higher expression of CD20 molecules on SLVL cells. CD55 and CD59 were not different between CLL and SLVL. Cold anti-CD20 plus gamma radiation induced less apoptosis than 213Bi conjugated anti-CD20 in CLL but not in SLVL.
P52 COLD AND ALPHA-CONJUGATED ANTI-CD20 INDUCE DIFFERENT IN VITRO APOPTOSIS REPONSES IN B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL) AND SPLENIC LYMPHOMA WITH VILLOUS LYMPHOCYTES (SLVL
P53 PROTEINATED SUBNANOPARTICLES OF COLLOIDAL SELENIUM:
A NEW CLASS OF ANTI-LEUKEMIA/LYMPHOMA AGENTS F. Sieber Medical College of Wisconsin, MILWAUKEE, WI, United States of America When selenomerocyanine or selenooxonol dyes are photobleached in the presence of serum albumin or certain serum lipoproteins, they generate subnanoparticles of colloidal selenium (selenium in oxidation state zero) that combine with the serum (lipo)protein to form stable conjugates that are very toxic to leukemia and lymphoma cells but well tolerated by normal hematopoietic stem and progenitor cells. A one-hour exposure to micromolar concentrations of Se(0)-protein conjugates is sufficient to eliminate >=5 log of in vitro clonogenic L1210, L1210/L-PAM1, L1210/L-PAM2, HL-60, K562, and Daudi leukemia/lymphoma cells but does not affect normal murine and human CD34+ hematopoietic stem cells and has little or no effect on granulocyte macrophage progenitors (CFU-GM). Se(0)-protein conjugates potentiate the anti-tumor effect of ionizing radiation and several antineoplastic drugs. For example, if a non-cytotoxic concentration (3 mg/ml, 30 min) of Amifostine is combined with Se(0)-protein conjugates (0.026 mM, 60 min), the depletion of L1210 leukemia cells is enhanced from 7 log to 12 log (depletions in excess of 6 log estimated from linear extrapolations of survival curves) whereas the recovery of normal CD34+ cells remains at 100%. Differential toxicity appears to be primarily the result of differential conjugate binding/uptake. Se(0)-protein conjugates enter target cells by an energy-dependent endocytotic process. The non-cytotoxic protein component serves as a delivery vehicle (Trojan horse) whereas Se(0) is the cytotoxic entity. Internalization of Se(0)-protein conjugates is followed by a rapid and massive (up to 80%) drop of intracellular glutathione, the activation of caspases, and a breakdown of the mitochondrial potential. Conjugates that are derived from merocyanine dyes that contain a sulfur or selenium atom in the donor heterocycle are intensely green-fluorescent due to the binding of a chromophore product to the albumin carrier molecule. The fluorescent label facilitates the monitoring of binding/uptake kinetics and the identification of conjugate-sensitive cell populations. Our results challenge the long-held dogma that selenium zero is biologically inert. They suggest that compounds modeled after our Se(0)-protein conjugates may prove useful for the systemic therapy of leukemia and lymphoma. Matrix metalloproteinases (MMPs), especially MMP-2 and -9, are thought to play a role in new vessel formation, also seen in acute myeloid leukemia (AML) (de Bont et al. Br J Haematol 2001) . MMP-9 knock-out mice also show a role of MMP-9 in mobilisation (Heissig et al. Cell 2002) . AML-cells are capable of expressing MMP-2 and -9 protein however, their role in AML is still not known. We investigated whether MMP-2 and -9 protein expression by AML cells correlated with the degree of vesseldensity in vivo and/or with numbers of leukemic cells in peripheral blood. Leukemic blasts were isolated from bone marrow of 36 AML patients. From 18 AML patients also bone marrow biopsies were available. Peripheral white blood cell count (WBC), absolute peripheral blood blast number (PB-blast) and cytogenetic characteristics of the leukemic cells were available. MMP-2 and -9 protein, hereafter called MMP-2 or -9, were measured in conditioned media by ELISA. Mean vessel density (MVD) was measured immunohistochemically by factor VIII staining. No correlation was found between MVD and MMP-2 (N=17 p=0.139 cc=-0.374) or MMP-9 (N=16 p=0.799 cc=-0.069). These results can not exclude involvement of MMP-2 or -9 from AML-cells in vesseldensity however, this suggests that MMP-2 and/or MMP-9 expression are not a critical step. No correlation was found between WBC and MMP-2 (N=36 p=0.932 cc=0.015) or MMP-9 (N=35 p=0.588 cc=0.095). Moreover PB-blast did not correlate with MMP-2 (N=34 p=0.828 cc=0.039) or MMP-9 (N=33 p=0.722 cc=0.064). When classifying patients according to cytogenetic characteristics into favourable (inv(16), t(15:17) and t(8:21), N=12) and non-favourable group (N=24), the favourable group expressed higher levels of MMP-2 compared to the non-favourable group (p=0.047).
In conclusion, we have shown that AML-related MMP-2 and/or -9 expression may not be critical factors in vesseldensity however, involvement is still possible. Moreover, peripheral blood blasts did not correlate with MMP-2 or -9 expression. Interestingly, MMP-2 expression correlated to favourable cytogenetics in AML. Further studies are warranted to investigate whether MMP-2 might be a prognostic factor and/or involved in leukemic cell growth. Objectives of the study: to estimate the efficiency of the new programs of chemotherapy of Hodgkin's disease in children by analysing the nearest and remote results of treatment. Methods. 29 children with primary Hodgkin's disease, that were treated at Pediatric Oncology Department from 1996 through 2001 have been included in the research. There were the following areas of localization of the tumor process: peripherial lymphonoduses -10, combined lesions -19 patients. The following stages of the disease have been diagnosed: I-A -9, II-A -11, II-B -5, III-A -2, IV-A -2 patients. The combination therapy of Hodgkin's disease -chemotherapy (COPP or ACOPP) and radiation therapy were conducted till 1999. Several treatments were carried out since: patients with stages I and II disease -4 courses of chemotherapy by scheme of COAP-1: Vincristine -1,4 mg/m2 on days 1 and 8; Cyclophosphamide --600 mg/m2 on days 1 and 8; Doxorubicin -40 mg/m2 on day 15; Prednisone -30 mg/m2 on days 1-14 (repead cycle every 28 days) and course of consolidation radiotherapy on zones of primary damage. Patients with stages III and IV disease -4 courses of inductive chemotherapy by scheme of COAP-2: Vincristine -1,4 mg/m2 on days 1 and 8; Cyclophosphamide --600 mg/m2 on days 1 and 8; Doxorubicin -40 mg/m2 on days 3 and 15; Prednisone -40 mg/m2 on days 1-14 (repead cycle every 28 days), course of consolidation radiotherapy on zones of primary damage and 2 courses of reinductive chemotherapy by scheme of COAP-1. Results. There are more cases of complete remission (100% vs 88%). The using of antitumor antibiotic -Doxorubicin and exclusion from scheme of chemotherapy Procarbazine in the investigated group of patients improved the remote results of treatment -long-lived (more than 1,5 years) disease free survival rate have been improved -from 63% to 85%. T(11;18)(q21;q21) resulting in the API2-MALT1 fusion transcript is an exclusive finding in extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT-lymphoma). While it has recently been demonstrated as a negative predictor for gastric MALT lymphoma undergoing eradication of Helicobacter pylori (HP), nothing is known about the relation between t(11;18)(q21;q21)-status and response to chemotherapy. We have therefore performed a retrospective analysis of t(11;18)(q21;q21) in patients undergoing chemotherapy with the nucleoside analogue cladribine (2CdA) for gastric MALTlymphoma. Seventeen cases treated with 2CdA were investigated for t(11;18)(q21;q21) by RT-PCR. t(11;18)(q21;q21) was correlated with response to chemotherapy. Nine cases were at stage IE, 2 stage IIE and 6 stage IV. Eight cases with stage IE lymphoma underwent HP eradication, but none of them showed regression during a minimum follow-up of 12 months and they were subsequently treated with chemotherapy. One patient received chemotherapy due to absence of HPinfection. Another patient initially rated as stage IE whose gastric lymphoma did not respond also developed spread to the lung during follow-up after eradication. All the remaining cases were treated by chemotherapy at the time of diagnosis. Out of these 17, eight patients were found to carry the t(11;18)(q21;q21)-translocation (47%). One patient, who was negative for t(11;18)(q21;q21) progressed during chemotherapy and died 5 months after initiation of treatment. One patient each with and without t(11;18)(q21;q21) had a partial response (PR) lasting for 14 and 18 + months, respectively. One t(11;18)(q21;q21) positive patient had stable disease for 16 + months. The remaining patients achieved a complete remission (CR) following treatment; six were positive for t(11;18)(q21;q21), while the remaining six were negative. Two patients (one positive and one negative for t(11;18)(q21;q21), respectively) have developed a local relapse following CR and were salvaged by radiotherapy. Our findings suggest that the presence of the API2-MALT1 fusion transcript resulting from t(11;18)(q21;q21) does not adversely affect response of gastric MALT lymphoma to chemotherapy with 2CdA. 2CdA appears to be an attractive agent for treatment of gastric MALT lymphoma unresponsive to H. pylori eradication, including those positive for t(11;18)(q21;q21).
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P58 T(11;18) TRANSLOCATION IN MALT LYMPHOMA DOES NOT INFLUENCE 18F-FLUORODEOXYGLUCOE-POSITRON EMISSION TOMOGRAPHY (18F-FDG-PET) RESULTS
M. Hoffmann, B Streubel, A. Chott, K Kletter, M Raderer University of Vienna, VIENNA, Austria T(11;18) is a translocation exclusively detected in extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma). MALT lymphomas harbouring t(11;18) usually not respond to eradication of Helicobacter pylori and are characterized by a more aggressive clinical behaviour and early dissemination as compared to t(11;18) negative cases. In order to evaluate whether this is associated with an increased glucose metabolism of lymphoma cells, we have performed a study using 18F-fluorodeoxy-glucose positron emission tomography (18F-FDG-PET) for in vivo assessment of tumor cell glucose uptake. A total of 22 patients with histologically verified MALT lymphoma of various localizations underwent 18F-FDG-PET scanning. Whole body 18F-FDG-PET scans were performed on a GE advanced PET scanner 40 min after i.v.injection of 300-380 MBq of 18F-FDG. For improvement of image quality patients had to fast for at least 4 hours prior to FDG-application. Scan results were evaluated from axial, coronal and sagittal images in a single-blinded way, i.e. without prior information of tumor spread. Evaluation of t(11;18) status was done using RT-PCR performed on paraffin-embedded specimens obtained from all patients. Eleven out of 22 patients (45%) patients tested positive for t(11;18). Seven had gastric MALT lymphoma, two had disease originating in the lung and two in the salivary glands. Six of these patients had disseminated disease, while an additional three cases had a local relapse following initial treatment. As opposed to this, only two out of the 11 t(11;18)-negative patients had disease relapse at the time of PETimaging. No difference in terms of proliferative activity as assessed by Ki-67 staining was seen between the two groups. In terms of scaning results, however, no differences could be detected between the two groups of patients, as no positive scans were obtained. One t(11;18)+ patient, however, had a positive 18F-FDG-PET following therapy with rituximab. Histologic assessment, however, showed transformation to an exclusive plamacell histology within the lymphoma. We conlcude that the more aggressive clinical course of t(11;18)+ MALT lymphomas is not reflected by enhanced proliferative activity or increased glucose utilization. The MMR pathway is a post-replicational DNA repair system that maintains genetic stability by repairing mismatched bases and insertion deletion loops mistakenly incorporated during DNA replication and deficiencies in proteins pivotal to this pathway result in a higher mutation rate, particularly at microsatellites. Although MMR defects have been identified in a variety of haematological malignancies, their involvement in plasma cell dyscrasias has not been investigated. Genetic instability is a prominent feature in multiple myeloma and progression of this disease from monoclonal gammopathy of uncertain significance (MGUS) and smouldering myeloma (SMM) is associated with increasing molecular and chromosomal abnormalities. We have investigated the functional proficiency of the MMR pathway in clinical samples and myeloma cell lines by microsatellite analysis and an in vitro heteroduplex G:T repair assay. Microsatellite analysis was performed using fluorescent-labelled products that were analysed by capillary electrophoresis (CEQ 2000, Beckman Coulter) . Initial analysis of 9 loci showed instability at one or more loci in 15 from 92 patients: 7.7% of MGUS/SMM, 19.3% of MM/plasma cell leukaemia (PCL) and 25% of relapsed MM/PCL. Using the repair assay evidence of reduced repair was found in 2 cell lines, JIM1 and JIM3 and in 2 of 4 PCL. Reduced repair in each case was associated with aberrant expression of at least one mismatch repair protein.
Microsatellite instability has been shown in mononucleotide repeats in coding regions of a variety of genes, in particular TGFbetaRII and BAX, and results in frameshift mutations and a truncated functionless protein. We analysed repeats in coding regions of TGFbeta RII, BAX, RHAMM and RIZ but no defects were found in either cell lines or clinical samples. Thus we show that MMR defects are found in plasma cell dyscrasias and the increased frequency during more active stages of disease suggests a contributory role in disease progression. Microsatellite instability in the downstream targets TGFbeta RII, BAX, RHAMM and RIZ has not been demonstrated. Chromosomal translocations involving a t(14;18)(q32;q21) and the chromosome 3q27 region are common in B-cell non-Hodgkin's lymphoma (NHL) of germinal center cell origin. Grade 3B follicular large cell lymphoma (FLCL), consisting almost exclusively of centroblasts, is a distinct subgroup of follicular lymphomas which has clinically more in common with the aggressive B-DLCL's than with their indolent follicular lymphoma grade 1 and 2 counterparts. We studied the cytogenetic and molecular genetic aberrations by classical cytogenetics, PCR, Southern Blot hybridization (SB) and fluorescence in situ hybridization (FISH), with special emphasis on t(14;18), affecting bcl-2, and 3q27 rearrangement, affecting bcl-6, in 32 cases of FLCL grade 3B. Three distinctive subgroups were identified based upon the existence of breakpoint 3q27, a translocation t(14;18) or the absence of both. Group I: with a t(14;18) and no 3q27 aberrations (n=13); group II: without a t(14;18) and without 3q27 aberrations (n=9), but with other cytogenetic aberrations; group III: without a t(14;18) but with aberrations involving 3q27 (n=10). None of the FLCL grade 3B cases was found to harbour both a t(14;18) and 3q27 aberration. These results, in particular the finding of a mutual exclusiveness of bcl-2 and bcl-6 rearrangement, indicate at least three different pathways of oncogenesis in follicular large cell lymphoma, grade 3B. FLCL 3B with bcl-2 rearrangement probably is part of the same entity as the other follicular lymphomas (grade 1,2,3A), whereas the cases with 3q27 abnormalities or other unrelated translocations are more closely related to the majority of diffuse large cell lymphomas of germinal center cell origin. The molecular events that precede the development of blast crisis (BC) in CML are poorly understood. To elucidate mechanisms of CML progression, we performed suppression subtractive hybridization on sequentially stored peripheral blood mononuclear cells from early chronic phase, late chronic phase and BC of a single CML patient. Twenty-six differentially expressed genes could thus be identified. Among these were inflammation related genes, heat shock proteins, tumor-suppressor genes, apoptosis related genes and interleukins. One of the genes that was upregulated in late chronic phase CML was interleukin-8 (IL-8), which has mitogenic and angiogenic properties in several human cancers. We hypothesized that upregulation of IL-8 might therefore also play a role in disease transformation in CML. We determined mRNA expression levels of IL-8 by quantitative PCR (LightCycler) in samples of 6 other CML-patients, collected at regular intervals during the course of disease. In all 7 conservatively treated patients that developed BC, a peak in IL-8 mRNA expression was found in late chronic phase. The median interval between peak level and the clinical manifestations of BC was 517 days (range 191-2485 days). The median increase in IL-8 mRNA expression at peak level was 21-fold (range 2-151) times the value found at diagnosis and this increase was unrelated to treatment type (interferon or hydroxyurea), total leukocyte-or monocyte counts. At BC, IL-8 levels were back at the level of that at diagnosis. Upregulation of IL-8 was also found in 7 CML patients who had no cytogenetic response but had not developed BC thus far and in 4 patients who were complete cytogenetic responders to interferon-alfa. At diagnosis and in chronic phase, levels of expression were not significantly different between the three groups. We conclude that in all patients with CML, there is an unexplained upregulation of IL-8 mRNA, irrespective of their response to conventional treatment. In BC patients, the IL-8 surge precedes the BC for one year or more. Whether this finding has implication for the pathophysiology of disease transformation in CML is unknown, but deserves further study, as is the case with the other 25 differentially expressed genes.
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P62 TRANSIENT ISCHEMIC ATTACKS (TIA`S) AS PRODROMAL SYMPTOMS IN A PATIENT WITH MOSCHOVIC SYDROME AND MULTIPLE SCLEROSIS (MS).
D. Kountouris, K. Koutsoubelis Center for Neurological Diagnosis, ATHENS, Greece Background: It is well known that Moschovic syndrome, before its appearance may present itself as a multisystem disorder. It also may present co morbidity with autoimmune disorder, like MS. There are reports where it is possible to appear without specific prodroms symptoms. We observed a case of a patient with MS and TIA`s as prodromal symptoms. Case Report: It is as about a woman 44 years old with free anamneses symptoms. The patient manifested Moschovic Syndrome with microamoragic symptoms, weakness and fatigue. The blood tests showed anemia and PLT: 50.000/ml. Since that time the prices of RLT fluctuated from 50.000-103.000/ml. Two years after the Moschovic Syndrome had appeared the patient was diagnosed with MS. The symptoms were spastic tetraparesisa and nystagm, 7,5 according to Kurtzke EDSS, after the medical treatment it was 1,5. Conclusion: The appearance of TIA`s may be prodrom symptoms of rare nosological combination. Particularly as a prodrom symptom-Moschovic is reported for first time. This pinpoints the necessity of all the diagnostic tests when there is a clinical appearance of TIA`s. Aplidine is a novel depsipeptide isolated from the sea tunicate A. Albicans. Phase I clinical studies have been completed with evidence of a positive therapeutic index (TI). The dose limiting toxicity was found to be muscular, without bone marrow toxicity. Clinical benefits were noted in different solid tumors and the compound is now in phase II clinical trials. Mechanistic studies indicate that Aplidine can block VEGF secretion in ALL-MOLT4 cells and in vitro cytotoxic activity at low concentrations (5nM) has been observed in AML and ALL samples from pediatric patients with de novo or relapsed ALL and AML. Aplidine appears to induce both a G1 and a G2 arrest in drug treated leukemia cells in vitro. Apart from down regulation of the VEGF receptor, little else is known about the mode(s) of action of Aplidine. In order to study the possible potentiation of other anticancer agents we have initiated a systematic study of drug combinations for possible use in leukemias and lymphomas. Aplidine was found to be an effective in vitro cytotoxic agent against primary cells from a patient with preB-ALL (DM4) as well as against fresh cells obtained from six chronic lymphocytic leukemia patients. The IC50 value was 10 nM, for 3day exposure with the DM4 line and after a 11day exposure with the primary CLL samples.Such IC50 correlates with the plasma levels achievable well below the recommended dose in patients. Drug combination studies were carried out on established cell lines rather than primary cells. We studied three cell lines viz. K562, CEM and SKI-DLCL representing acute myeloid leukemia, acute lymphocytic leukemia and diffuse large cell lymphoma respectively. The preliminary data shows that Aplidine potentiates the effect of methotrexate, cytosine arabinoside as well as doxorubicin in K562 cells by lowering the IC50s for the drugs. Future studies will be designed to extend these observations which may lead to the design of clinical combination studies and may also help in understanding the mechanism of action of Aplidine.
